MindImmune Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Rhode Island, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
130 Flagg Rd, Kingston, Rhode Island, 02...Phone Number
(401) 225-4612Website
www.mindimmune.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About MindImmune Therapeutics
MindImmune Therapeutics is a biotechnology company developing products that target the immunological drivers of neurodegenerative disease. Its lead program, MITI-101, is designed to block the harmful recruitment of peripheral immune cells into the brain in patients with Alzheimers disease and other neurodegenerative conditions.Explore more
MindImmune Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MindImmune Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on MindImmune Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at MindImmune Therapeutics
Check if MindImmune Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if MindImmune Therapeutics had a recent Job posting/layoffs
Check out if MindImmune Therapeutics is spiking on competitors!
MindImmune Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when MindImmune Therapeutics launches new products
Funding: Get notified immidiatlly once MindImmune Therapeutics has new funding data
Recommended Actions
Reach out to Masked Content who joined MindImmune Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to MindImmune Therapeutics
Compare insights from companies similar to MindImmune Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$6.6M
11-50
Private
-
-
DE
Darren EngersSenior Director of Medicinal Chemistry, Research Assistant Professor of Pharmacology
<$5M
1-10
Private
-
2011
Mark KlevenSenior Vice President, Scientific Operations, Chief Operating Officer
Company Profile Activity
Activity Insights
MindImmune Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MindImmune Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MindImmune Therapeutics.
MindImmune Therapeutics financials insights
Gather financial insights about MindImmune Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Angel/Seed
$500K
2017
Unspecified
$250K
2021
Debt
$57K
2025
Series A
$30M
2026
Unspecified
$5M
MindImmune Therapeutics Tech Stack
A closer look at the technologies used by MindImmune Therapeutics
See more technologies
Most Recent Scoops
Funding
Funding
Funding
Funding
Funding
Funding
MindImmune Therapeutics News & Media
Wheeler Bio and MindImmune Therapeutics Sign CDMO Partnership Agreement to Support MindImmune's Lead Alzheimer's Prevention Program, MITI-101
OKLAHOMA CITY, Sept. 17, 2025 /PRNewswire/ -- Wheeler Bio, a U.S.-based contract development and biomanufacturing organization (CDMO), today announced it has entered into an agreement with MindImmune Therapeutics, a biopharmaceutical company focused on neuroinflammation and Alzheimer's...MindImmune Awarded Grant to Accelerate IND-Enabling Studies through Rhode Island Life Science Hub
SOUTH KINGSTON, R.I.--(BUSINESS WIRE)--MindImmune Therapeutics, a biopharmaceutical company focused on neuroinflammation and Alzheimer’s disease, today announced it has been awarded a grant by Rhode Island Life Science Hub to accelerate the company’s preclinical development work on MITI-101, its monoclonal antibody designed to prevent the recruitment of neuro-inflammatory innate immune cells from the periphery into the brain. MITI-101 is under development for the treatment of mild-to-moderate A
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MindImmune Therapeutics
Sign Up For FreeTo access detailed company insights
MindImmune Therapeutics is a biotechnology company developing products that target the immunological drivers of neurodegenerative disease. Its lead program, MITI-101, is designed to block the harmful recruitment of peripheral immune cells into the brain in patients with Alzheimers disease and other neurodegenerative conditions.... Read More
